What is Greenwich LifeSciences Operating Cash Flow per Share?
Greenwich LifeSciences's operating cash flow per share for the
three
months ended in Mar. 2024 was $-0.14.
Greenwich LifeSciences's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.52.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -60.90% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -132.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Greenwich LifeSciences's Operating Cash Flow per Share or its related term are showing as below:
GLSI'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -221.4 Med: -171.4 Max: -60.9
Current: -60.9
During the past 6 years, Greenwich LifeSciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was -60.90% per year. The lowest was -221.40% per year. And the median was -171.40% per year.
GLSI's 3-Year OCF Growth Rate is ranked worse than 91.82% of 1234
companies
in the Biotechnology industry
Industry Median: 3.5
vs GLSI: -60.90
Greenwich LifeSciences Operating Cash Flow per Share Historical Data
The historical data trend for Greenwich LifeSciences's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Greenwich LifeSciences Operating Cash Flow per Share Chart
Competitive Comparison of Greenwich LifeSciences's Operating Cash Flow per Share
For the Biotechnology subindustry, Greenwich LifeSciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greenwich LifeSciences's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Greenwich LifeSciences's Price-to-Operating-Cash-Flow falls into.
Greenwich LifeSciences Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Greenwich LifeSciences's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.52
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Greenwich LifeSciences Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Greenwich LifeSciences's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Greenwich LifeSciences (Greenwich LifeSciences) Business Description
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells in order to inhibit the spread of cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GLSI has been successfully added to your 